A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma

Abstract Background Most ovarian cancer patients are diagnosed at a late stage with 85% of them relapsing after surgery and standard chemotherapy; for this reason, new treatments are urgently needed. Ovarian cancer has become a candidate for immunotherapy by reason of their expression of shared tumo...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Apostolos Sarivalasis, Caroline Boudousquié, Klara Balint, Brian J. Stevenson, Philippe O. Gannon, Emanuela Marina Iancu, Laetitia Rossier, Silvia Martin Lluesma, Patrice Mathevet, Christine Sempoux, George Coukos, Urania Dafni, Alexandre Harari, Michal Bassani-Sternberg, Lana E. Kandalaft
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2019-11-01
coleção:	Journal of Translational Medicine
Assuntos:	Ovarian cancer Dendritic cell vaccine Neoantigen Neoepitope Cancer immunotherapy Cyclophosphamide
Acesso em linha:	http://link.springer.com/article/10.1186/s12967-019-02133-w
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!